Vaccine Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Inactivated Vaccine, DNA Vaccines, Attenuated Vaccine, Toxoid Vaccines, Subunit Vaccines); By Application; By Process; By Region; Segment Forecast, 2023-

Vaccine Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Inactivated Vaccine, DNA Vaccines, Attenuated Vaccine, Toxoid Vaccines, Subunit Vaccines); By Application; By Process; By Region; Segment Forecast, 2023- 2032

The global vaccine contract manufacturing market size is expected to reach USD 13.16 billion by 2032, according to a new study by Polaris Market Research. The report “Vaccine Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Inactivated Vaccine, DNA Vaccines, Attenuated Vaccine, Toxoid Vaccines, Subunit Vaccines); By Application; By Process; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Pharmaceutical and biopharmaceutical companies are strategically prioritizing their core competencies to navigate the escalating price pressures. Consequently, there is a growing inclination towards contract manufacturing.

However, vaccine production presents a complex challenge for manufacturers as they strive to guarantee safety, effectiveness, and consistency. The vaccine contract manufacturing market is driven by a diverse range of services encompassing production processes, the establishment and operation of manufacturing facilities, cell line development, fermentation, process refinement, and analytical characterization. These services collectively play a pivotal role in driving the market's substantial growth on a worldwide level.

Vaccination plays an important role in enhancing both human and veterinary health. It not only diminishes reliance on antibiotics but also serves as a potent deterrent against various diseases. The escalating recognition of its manifold advantages, which include safeguarding against severe illnesses and infectious conditions, is fueling the call for widespread immunization initiatives and inoculation programs. In tandem with this, the cognizance of the substantial capital outlay needed for production has prompted major pharmaceutical entities to opt for outsourcing in the realm of vaccine manufacturing.

However, in low-resource countries, the shortage of equipment and proficient labor for vaccine production is a significant factor driving the expansion of the global vaccine contract manufacturing market. Additionally, the introduction of advanced expression systems such as EB66 and GPEx, along with innovative cell culture media platforms, is providing substantial support for market growth. Furthermore, the surging instances of COVID-19 in various nations have prompted vaccine developers to engage in outsourcing agreements with Contract Manufacturing Organizations (CMOs), fostering a positive trajectory for market advancement.

Vaccine Contract Manufacturing Market Report Highlights

The Inactivated Vaccine segment is expected to witness the fastest CAGR during the forecast period on account of better efficiency.

The veterinary segment held a significant share in revenue share in 2022, which is mainly driven by increased utilization of CMOs in the production of animal vaccinations.

In 2022, the downstream segment held the largest market share due to technological advancements and innovation.

In 2022, the North American region held the largest market share, owing to exponential growth in technology and rising R&D investments.

The global key market players include Fujifilm Diosynth Biotechnologies, IDT Biologika GmbH, KBI Biopharma, Lonza Group, Merck KGaA, and more.

Polaris Market Research has segmented the vaccine contract manufacturing market report based on vaccine type, application, process, and region:

Vaccine Contract Manufacturing, Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

Inactivated Vaccine

DNA Vaccines

Attenuated Vaccine

Toxoid Vaccines

Subunit Vaccines

Vaccine Contract Manufacturing, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Human

Veterinary

Vaccine Contract Manufacturing, Process Outlook (Revenue - USD Billion, 2019 - 2032)

Upstream

Downstream

Vaccine Contract Manufacturing, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa